Erin E. Mulvihill
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
S Intermittent fasting (IF) improves metabolic health, yet the requirement for hepatic ketogenesis in mediating these benefits remains unclear. Here, we investigated how hepatic ketogenesis contributes to the metabolic and hepatic effects of IF in male and female mice. In the human liver, ketogenesis-associated genes showed sex-dependent correlations with inflammatory and fibrotic pathways. In mice, fasting increased circulating ketone bodies, with females exhibiting a greater rise, indicating intrinsic sex differences in ketone metabolism. IF reduced body weight and adiposity in both sexes, and these systemic benefits persisted despite antisense oligonucleotide (ASO)-mediated knockdown of hepatic Hmgcs2 . In contrast, hepatic benefits were sex- and ketogenesis-dependent. IF markedly reduced steatosis and fibrosis in male mice, but these improvements were attenuated or abolished when hepatic ketogenesis was disrupted. Female mice showed minimal hepatic benefit from IF and displayed heightened susceptibility to steatosis, fibrosis, and inflammatory activation under ketogenic insufficiency. Single-cell transcriptomic analyses identified neutrophils and myofibroblasts as key responders to hepatocyte-derived ketone bodies, and IF suppressed neutrophil-driven inflammatory signaling in a ketogenesis-dependent manner in males but not females. Together, these findings demonstrate that while systemic metabolic improvements from IF are largely ketogenesis-independent, the hepatic anti-steatotic and anti-fibrotic effects of IF are sexually dimorphic and require intact hepatic ketogenesis.
Year:
2025
The association between metabolic dysfunction–associated steatotic liver disease (MASLD) and cardiovascular disease is well characterized; however, the underlying mechanism is incompletely understood. Interestingly, hepatocyte‐specific silencing of dipeptidyl peptidase 4 (DPP4) prevents liver fibrosis and adipose tissue inflammation; however, how this affects the heart remains to be investigated. This study evaluates how diastolic function and molecular signatures of heart failure, like inflammation and fibrosis, are affected in male Dpp4+/+ , Dpp4−/− , and Dpp4flox/flox mice injected with a TBG‐CRE to selectively eliminate DPP4 from hepatocytes ( Dpp4hep−/− ) and respective controls ( Dpp4GFP ), aged and fed an HFHC diet for 24 weeks. Mice underwent pulsed‐wave and tissue Doppler echocardiography. Further, speckle‐tracking strain analysis was performed to detect diastolic dysfunction. Differential mRNA analysis using the NanoString platform and qRT‐PCR were conducted using ventricular tissue to assess immunological pathway expression, as well as hypertrophy, modeling‐related, senescence, and metabolism gene expression. Immunological pathway analysis of ventricular tissue revealed downregulation of 12 immune‐related pathways in Dpp4hep−/− mice, including apoptosis and chemokine and cytokine signaling; however, this was not observed in Dpp4−/− mice. Further, fibrosis and ECM modeling‐related genes, Col1a1 , Col3a1 , Ctgf , and Myh7 , were significantly upregulated in Dpp4−/− mice but unchanged in Dpp4hep−/− mice, compared to controls. Interestingly, cardiac hypertrophy and systolic and diastolic function evaluated with echocardiography were unchanged. Immune‐related pathways are downregulated in Dpp4hep−/− mice, while fibrosis genes are significantly upregulated in Dpp4−/− mice, compared to respective controls. Despite these molecular changes, cardiac hypertrophy and systolic and diastolic function were unchanged with systemic and organ‐specific loss of Dpp4 .
Year:
2025
This study identified novel changes in the proteome of mitochondrial supercomplexes in a murine model of heart failure, including alterations in the relative abundance of metabolic protein complexes, redox proteins, and ribosomal proteins. These findings provide new insights into potential mechanisms that may contribute to metabolic dysfunction in heart failure.
Year:
2025
Statins are a commonly prescribed cholesterol lowering drug class that can increase the risk of new-onset diabetes (NOD). To investigate the molecular mechanisms underlying this effect, we generated human induced pluripotent stem cells (iPSCs) from individuals identified from electronic health records of Kaiser Permanente of Northern California who were susceptible to developing NOD after statin initiation or controls who maintained stable fasting glucose on statin treatment. RNA-seq analysis of iPSCs incubated with atorvastatin, simvastatin or mock buffer for 24 hours identified the long non-coding RNA MIR194-2HG as a top candidate gene. Statin-induced increases in its expression were observed in NOD resistant controls, while statin-induced reductions occurred in NOD susceptible cases. MIR194-2HG encompasses two microRNA genes: MIR192 and MIR194-2 . The mature microRNA miR-192-5p, derived from the 5’ arm of MIR192 , was predicted to bind the 3’UTR of the glucagon like peptide 1 (GLP-1) receptor ( GLP1R ) transcript. Transfection of a rat insulinoma cell line INS-1 with a miR-192-5p mimic increased Glp1r transcript (1.41-fold) and protein (1.51-fold) levels compared to a scrambled control. Using a luciferase reporter containing the human GLP1R 3’UTR, miR-192-5p overexpression similarly increased luciferase signal (1.44-fold). The miR-192-5p mimic enhanced glucose stimulated insulin secretion (GSIS) in response to GLP1R agonists (1.64-1.81-fold) and rescued simvastatin-induced GSIS impairment in INS-1 cells. Wild-type mice treated with miR-192 AAV8 had improved glucose sensitivity. Islets isolated from these mice exhibited enhanced GLP-1 potentiated GSIS during perifusion ex vivo . These effects were absent in the DIRKO ( Glp1r/Gipr double knockout) mouse islets, consistent with the idea that miR-192 promotes GLP-1 mediated GSIS through GLP1R. These findings implicate MIR192 in statin-induced impairment of GSIS by modulating GLP1R, potentially contributing to the susceptibility to NOD in statin users.
Year:
2025
Introduction The COVID-19 pandemic disrupted research globally. How it impacted Canadian early-career health researchers (ECHRs) remains unclear. We administered a survey to understand the composition of ECHRs in Canada, their job experiences, and experiences of burnout during the COVID-19 pandemic. Methods A cross-sectional survey was conducted in May 2023 of Canadian ECHRs defined as within 7 years of their first independent research position. Quantitative analyses included a description of respondents by research pillar, socio-demographic and workplace characteristics, and the prevalence of burnout, disengagement or exhaustion. Sample characteristics were compared to national data on ECHRs from a Canadian funding agency. Thematic analysis of free-text responses was also conducted. Results A total of 225 respondents met the eligibility criteria. Most respondents were assistant professors and characteristics of our sample were like the national data. The COVID-19 pandemic posed many challenges to student recruitment, and emotional support of students, with over half of the respondents reporting a moderate to significant decline in mental health compared to pre-pandemic. A significant proportion of respondents were experiencing high burnout (62%, 95%CI:56-67%), exhaustion (64%, 95%CI: 57-70%) or disengagement (91%, 95%CI: 87-95%). Thematic analysis identified three themes: ongoing benefits/problems preceding the pandemic, unintended outcomes of strategies to manage/prevent/contain COVID-19, and reasons to stay in their current position. Conclusions Our survey revealed that Canadian ECHRs reported many diverse challenges during the COVID-19 pandemic and high burnout, putting the sustainability of this workforce at risk. Improved systems are needed to understand the long-term impacts and support the future of the Canadian health research ecosystem.
Year:
2024
Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower rates of myocardial infarction, and lower rates of stroke. The cardiovascular benefits observed following GLP-1RA treatment could be secondary to improvements in glycemia, blood pressure, postprandial lipidemia, and inflammation. Yet, the GLP-1R is also expressed in the heart and vasculature, suggesting that GLP-1R agonism may impact the cardiovascular system. The emergence of GLP-1RAs combined with glucose-dependent insulinotropic polypeptide and glucagon receptor agonists has shown promising results as new weight loss medications. Dual-agonist and tri-agonist therapies have demonstrated superior outcomes in weight loss, lowered blood sugar and lipid levels, restoration of tissue function, and enhancement of overall substrate metabolism compared to using GLP-1R agonists alone. However, the precise mechanisms underlying their cardiovascular benefits remain to be fully elucidated. This review aims to summarize the findings from CVOTs of GLP-1RAs, explore the latest data on dual and tri-agonist therapies, and delve into potential mechanisms contributing to their cardioprotective effects. It also addresses current gaps in understanding and areas for further research.
Year:
2024
Type 2 diabetes (T2D) is characterized by muscle metabolic dysfunction that exercise can minimize, but some patients do not respond to an exercise intervention. Myokine secretion is intrinsically altered in patients with T2D, but the role of myokines in exercise resistance in this patient population has never been studied. We sought to determine if changes in myokine secretion were linked to the response to an exercise intervention in patients with T2D. The participants followed a 10-week aerobic exercise training intervention, and patients with T2D were grouped based on muscle mitochondrial function improvement (responders versus non-responders). We measured myokines in serum and cell-culture medium of myotubes derived from participants pre- and post-intervention and in response to an in vitro model of muscle contraction. We also quantified the expression of genes related to inflammation in the myotubes pre- and post-intervention. No significant differences were detected depending on T2D status or response to exercise in the biological markers measured, with the exception of modest differences in expression patterns for certain myokines (IL-1β, IL-8, IL-10, and IL-15). Further investigation into the molecular mechanisms involving myokines may explain exercise resistance with T2D; however, the role in metabolic adaptations to exercise in T2D requires further investigation.
Year:
2024
As the worldwide prevalence of diabetes and obesity continues to rise, so does the risk of debilitating cardiovascular complications. Given the significant association between diabetes and cardiovascular risk, the actions of glucose-lowering therapies within the cardiovascular system must be clearly defined. Incretin hormones, including GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), are gut hormones secreted in response to nutrient intake that maintain glycemic control by regulating insulin and glucagon release. GLP-1 receptor agonists (GLP-1Ras) and dipeptidyl peptidase 4 inhibitors (DPP-4is) represent two drug classes used for the treatment of type 2 diabetes mellitus (T2DM) that improve glucose regulation through stimulating the actions of gut-derived incretin hormones or inhibiting their degradation, respectively. Despite both classes acting to potentiate the incretin response, the potential cardioprotective benefits afforded by GLP-1Ras have not been recapitulated in cardiovascular outcome trials (CVOTs) evaluating DPP-4is. This review provides insights through discussion of clinical and preclinical studies to illuminate the physiological mechanisms that may underlie and reconcile observations from GLP-1Ra and DPP-4i CVOTs. Furthermore, critical knowledge gaps and areas for further investigation will be emphasized to guide future studies and, ultimately, facilitate improved clinical management of cardiovascular disease in T2DM.
Year:
2022
Collaborators (20)
Laura Anderson
McMaster University
Sarah Hewko
Assistant Professor
University of Prince Edward Island
Marisa Medina
Associate Professor
University of California, San Francisco
Glen F. Tibbits
Simon Fraser University
Grace Lam
Assistant Professor
University of Alberta
Akinyemi Oni‐Orisan
Associate Professor
University of California, San Francisco
Maria Aristizabal
Assistant Professor
Queen's University
Morgan D. Fullerton
University of Ottawa
Ayesha Saleem
Research Scientist
University of Manitoba
Kyoung-Han Kim
Assistant Professor
University of Ottawa
Céline Aguer
Assistant professor
McGill University
Annie Vogel Ciernia
Assistant Professor
The University of British Columbia
Joe Son
Assistant professor
Kyungpook National University
Maxime W C Rousseaux
University of Ottawa
Lubna Daraz
Assistant Professor
Université de Montréal
Kaarina Kowalec
Associate Professor
-
Mary-Ellen Harper
Professor
University of Ottawa
Elizabeth Theusch
Associate Researcher
University of California, San Francisco
Antoine Dufour
Professor
University of Calgary
Gareth Lim
Associate Professor
Université de Montréal
Make your next move.
Prepare your application
Review drafts before you send them.